Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

Alice K. Asher, Carmen J. Portillo, Bruce A. Cooper, Carol Dawson-Rose, David Vlahov, Kimberly A. Page

Research output: Contribution to journalArticle

Abstract

Background: Direct-acting antivirals (DAAs) are curative in most persons with chronic hepatitis C virus (HCV) infection. However, high cost and concerns about adherence and reinfection may present continued barriers to treatment, particularly for people who inject drugs (PWID). Objective: To understand changes in assessments of treatment candidacy, given advances in treatment. Methods: Clinicians attending the Liver Meeting® in 2014 who reported prescribing HCV treatment in the past three years were invited to complete a survey regarding HCV treatment decisions. Participants assessed their likelihood to treat HCV in PWID in association with time of abstinence from injection drug use and what impacts their decision to provide treatment using interferon and DAAs. Results: 108 clinicians completed the survey; 10% were willing to treat an active PWID (last injection within 30 days) using interferon-containing regimens, and 15% with all-oral regimens. For each increasing time interval of injection abstinence, there was an increase in the odds of a clinician reporting willingness to treat with DAAs (Odds Ratio (OR) 2.57, 95% CI 2.18, 3.03) and with interferon-based treatment (OR 2.22 (95% CI 1.90, 2.61), Reinfection and medication cost were cited as most important concerns when determining candidacy. Conclusions: A cure is now the norm in HCV treatment, and there is an increasing need to address the barriers to treating PWID, the population with the highest burden of infection. Understanding treatment candidacy assessments is essential to improving uptake. This study provides insight into how clinicians view treatment candidacy in this era of DAAs and can help identify supportive treatment environments and concurrent programs.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalSubstance Use and Misuse
DOIs
StateAccepted/In press - May 23 2016
Externally publishedYes

Fingerprint

Hepacivirus
Antiviral Agents
contagious disease
candidacy
drug
Pharmaceutical Preparations
Therapeutics
Interferons
costs
drug use
Injections
medication
Odds Ratio
Costs and Cost Analysis
human being
Chronic Hepatitis C
Virus Diseases
time
Liver

Keywords

  • abstinence
  • direct-acting antiviral hepatitis treatment candidacy
  • hepatitis C cure
  • Hepatitis C treatment
  • injection drug use
  • people who inject drugs (PWID)
  • providers

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Medicine (miscellaneous)

Cite this

Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs. / Asher, Alice K.; Portillo, Carmen J.; Cooper, Bruce A.; Dawson-Rose, Carol; Vlahov, David; Page, Kimberly A.

In: Substance Use and Misuse, 23.05.2016, p. 1-6.

Research output: Contribution to journalArticle

Asher, Alice K. ; Portillo, Carmen J. ; Cooper, Bruce A. ; Dawson-Rose, Carol ; Vlahov, David ; Page, Kimberly A. / Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs. In: Substance Use and Misuse. 2016 ; pp. 1-6.
@article{7f7fac06f265478ab9984938654ac8cb,
title = "Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs",
abstract = "Background: Direct-acting antivirals (DAAs) are curative in most persons with chronic hepatitis C virus (HCV) infection. However, high cost and concerns about adherence and reinfection may present continued barriers to treatment, particularly for people who inject drugs (PWID). Objective: To understand changes in assessments of treatment candidacy, given advances in treatment. Methods: Clinicians attending the Liver Meeting{\circledR} in 2014 who reported prescribing HCV treatment in the past three years were invited to complete a survey regarding HCV treatment decisions. Participants assessed their likelihood to treat HCV in PWID in association with time of abstinence from injection drug use and what impacts their decision to provide treatment using interferon and DAAs. Results: 108 clinicians completed the survey; 10{\%} were willing to treat an active PWID (last injection within 30 days) using interferon-containing regimens, and 15{\%} with all-oral regimens. For each increasing time interval of injection abstinence, there was an increase in the odds of a clinician reporting willingness to treat with DAAs (Odds Ratio (OR) 2.57, 95{\%} CI 2.18, 3.03) and with interferon-based treatment (OR 2.22 (95{\%} CI 1.90, 2.61), Reinfection and medication cost were cited as most important concerns when determining candidacy. Conclusions: A cure is now the norm in HCV treatment, and there is an increasing need to address the barriers to treating PWID, the population with the highest burden of infection. Understanding treatment candidacy assessments is essential to improving uptake. This study provides insight into how clinicians view treatment candidacy in this era of DAAs and can help identify supportive treatment environments and concurrent programs.",
keywords = "abstinence, direct-acting antiviral hepatitis treatment candidacy, hepatitis C cure, Hepatitis C treatment, injection drug use, people who inject drugs (PWID), providers",
author = "Asher, {Alice K.} and Portillo, {Carmen J.} and Cooper, {Bruce A.} and Carol Dawson-Rose and David Vlahov and Page, {Kimberly A.}",
year = "2016",
month = "5",
day = "23",
doi = "10.3109/10826084.2016.1161054",
language = "English (US)",
pages = "1--6",
journal = "Substance Use and Misuse",
issn = "1082-6084",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

AU - Asher, Alice K.

AU - Portillo, Carmen J.

AU - Cooper, Bruce A.

AU - Dawson-Rose, Carol

AU - Vlahov, David

AU - Page, Kimberly A.

PY - 2016/5/23

Y1 - 2016/5/23

N2 - Background: Direct-acting antivirals (DAAs) are curative in most persons with chronic hepatitis C virus (HCV) infection. However, high cost and concerns about adherence and reinfection may present continued barriers to treatment, particularly for people who inject drugs (PWID). Objective: To understand changes in assessments of treatment candidacy, given advances in treatment. Methods: Clinicians attending the Liver Meeting® in 2014 who reported prescribing HCV treatment in the past three years were invited to complete a survey regarding HCV treatment decisions. Participants assessed their likelihood to treat HCV in PWID in association with time of abstinence from injection drug use and what impacts their decision to provide treatment using interferon and DAAs. Results: 108 clinicians completed the survey; 10% were willing to treat an active PWID (last injection within 30 days) using interferon-containing regimens, and 15% with all-oral regimens. For each increasing time interval of injection abstinence, there was an increase in the odds of a clinician reporting willingness to treat with DAAs (Odds Ratio (OR) 2.57, 95% CI 2.18, 3.03) and with interferon-based treatment (OR 2.22 (95% CI 1.90, 2.61), Reinfection and medication cost were cited as most important concerns when determining candidacy. Conclusions: A cure is now the norm in HCV treatment, and there is an increasing need to address the barriers to treating PWID, the population with the highest burden of infection. Understanding treatment candidacy assessments is essential to improving uptake. This study provides insight into how clinicians view treatment candidacy in this era of DAAs and can help identify supportive treatment environments and concurrent programs.

AB - Background: Direct-acting antivirals (DAAs) are curative in most persons with chronic hepatitis C virus (HCV) infection. However, high cost and concerns about adherence and reinfection may present continued barriers to treatment, particularly for people who inject drugs (PWID). Objective: To understand changes in assessments of treatment candidacy, given advances in treatment. Methods: Clinicians attending the Liver Meeting® in 2014 who reported prescribing HCV treatment in the past three years were invited to complete a survey regarding HCV treatment decisions. Participants assessed their likelihood to treat HCV in PWID in association with time of abstinence from injection drug use and what impacts their decision to provide treatment using interferon and DAAs. Results: 108 clinicians completed the survey; 10% were willing to treat an active PWID (last injection within 30 days) using interferon-containing regimens, and 15% with all-oral regimens. For each increasing time interval of injection abstinence, there was an increase in the odds of a clinician reporting willingness to treat with DAAs (Odds Ratio (OR) 2.57, 95% CI 2.18, 3.03) and with interferon-based treatment (OR 2.22 (95% CI 1.90, 2.61), Reinfection and medication cost were cited as most important concerns when determining candidacy. Conclusions: A cure is now the norm in HCV treatment, and there is an increasing need to address the barriers to treating PWID, the population with the highest burden of infection. Understanding treatment candidacy assessments is essential to improving uptake. This study provides insight into how clinicians view treatment candidacy in this era of DAAs and can help identify supportive treatment environments and concurrent programs.

KW - abstinence

KW - direct-acting antiviral hepatitis treatment candidacy

KW - hepatitis C cure

KW - Hepatitis C treatment

KW - injection drug use

KW - people who inject drugs (PWID)

KW - providers

UR - http://www.scopus.com/inward/record.url?scp=84969850578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969850578&partnerID=8YFLogxK

U2 - 10.3109/10826084.2016.1161054

DO - 10.3109/10826084.2016.1161054

M3 - Article

SP - 1

EP - 6

JO - Substance Use and Misuse

JF - Substance Use and Misuse

SN - 1082-6084

ER -